{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:01:01Z","timestamp":1792612861479,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jbc.2026.113185","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T23:10:00Z","timestamp":1779750600000},"page":"113185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Low-dose EGFR inhibition unlocks ferroptosis susceptibility to sensitize chemotherapy in EGFR-high triple-negative breast cancer"],"prefix":"10.1016","volume":"302","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5399-5628","authenticated-orcid":false,"given":"Xiaoxi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1321-6524","authenticated-orcid":false,"given":"Ling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijun","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2026.113185_bib1","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.ccell.2023.07.013","article-title":"Clinical Proteomic Tumor Analysis Consortium (2023) integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin","volume":"41","author":"Liang","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2026.113185_bib2","first-page":"1","article-title":"Therapeutic advances of targeting receptor tyrosine kinases in cancer","volume":"9","author":"Tomuleasa","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jbc.2026.113185_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188789","article-title":"Can EGFR be a therapeutic target in breast cancer?","volume":"1877","author":"Li","year":"2022","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.jbc.2026.113185_bib4","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","article-title":"Advancing targeted protein degradation for cancer therapy","volume":"21","author":"Dale","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jbc.2026.113185_bib5","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41580-024-00729-9","article-title":"Targeted protein degradation: from mechanisms to clinic","volume":"25","author":"Tsai","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jbc.2026.113185_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","article-title":"The advantages of targeted protein degradation over inhibition: an RTK case study","volume":"25","author":"Burslem","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.jbc.2026.113185_bib7","doi-asserted-by":"crossref","first-page":"eadi5798","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.jbc.2026.113185_bib8","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","article-title":"Metastatic behavior of breast cancer subtypes","volume":"28","author":"Kennecke","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbc.2026.113185_bib9","first-page":"1","article-title":"Organotropism: new insights into molecular mechanisms of breast cancer metastasis","volume":"2","author":"Chen","year":"2018","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.jbc.2026.113185_bib10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer \u2014 expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jbc.2026.113185_bib11","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jbc.2026.113185_bib12","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/d41573-019-00074-z","article-title":"Trends in clinical success rates and therapeutic focus","volume":"18","author":"Dowden","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jbc.2026.113185_bib13","article-title":"Improving the predictive accuracy of efficacy evaluation using tumor orthotopic transplant and resection model","volume":"15","author":"Li","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jbc.2026.113185_bib14","article-title":"Excessive concentrations of kinase inhibitors in translational studies impede effective drug repurposing","volume":"4","author":"Liu","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.jbc.2026.113185_bib15","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41388-021-02086-9","article-title":"EGF-SNX3-EGFR axis drives tumor progression and metastasis in triple-negative breast cancers","volume":"41","author":"Cicek","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.jbc.2026.113185_bib16","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/s41388-019-1046-5","article-title":"HUNK phosphorylates EGFR to regulate breast cancer metastasis","volume":"39","author":"Williams","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.jbc.2026.113185_bib17","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/modpathol.2013.251","article-title":"High EGFR gene copy number predicts poor outcome in triple-negative breast cancer","volume":"27","author":"Park","year":"2014","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.jbc.2026.113185_bib18","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24816","article-title":"Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes","volume":"116","author":"Rimawi","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.jbc.2026.113185_bib19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10549-008-0055-9","article-title":"Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer","volume":"115","author":"Dickler","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jbc.2026.113185_bib20","first-page":"1398","article-title":"Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer","volume":"1","author":"Sainsbury","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.jbc.2026.113185_bib21","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41568-025-00817-8","article-title":"Targeted protein degradation for cancer therapy","volume":"25","author":"Hinterndorfer","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jbc.2026.113185_bib22","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nchembio.503","article-title":"A mammalian functional-genetic approach to characterizing cancer therapeutics","volume":"7","author":"Jiang","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.jbc.2026.113185_bib23","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41568-023-00557-7","article-title":"Nucleotide metabolism: a pan-cancer metabolic dependency","volume":"23","author":"Mullen","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jbc.2026.113185_bib24","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ccell.2017.08.008","article-title":"MUC1 and HIF-1alpha signaling crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer","volume":"32","author":"Shukla","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2026.113185_bib25","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1038\/s41467-023-38753-6","article-title":"Lysyl oxidase-like 3 restrains mitochondrial ferroptosis to promote liver cancer chemoresistance by stabilizing dihydroorotate dehydrogenase","volume":"14","author":"Zhan","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2026.113185_bib26","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41573-023-00833-z","article-title":"Extracellular targeted protein degradation: an emerging modality for drug discovery","volume":"23","author":"Wells","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jbc.2026.113185_bib27","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s41586-025-09763-9","article-title":"Inhibitors supercharge kinase turnover through native proteolytic circuits","volume":"649","author":"Scholes","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.jbc.2026.113185_bib28","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","article-title":"Targeting ferroptosis as a vulnerability in cancer","volume":"22","author":"Lei","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jbc.2026.113185_bib29","doi-asserted-by":"crossref","first-page":"9550","DOI":"10.1038\/s41467-024-53837-7","article-title":"Inhibition of GPX4 enhances CDK4\/6 inhibitor and endocrine therapy activity in breast cancer","volume":"15","author":"Herrera-Abreu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2026.113185_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074250","article-title":"SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis","volume":"8","author":"Aguirre-Gamboa","year":"2013","journal-title":"PLoS One"}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925826020570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925826020570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T23:36:48Z","timestamp":1786145808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925826020570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0021925826020570"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2026.113185","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose EGFR inhibition unlocks ferroptosis susceptibility to sensitize chemotherapy in EGFR-high triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2026.113185","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"113185"}}